Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
An old cancer drug's degrading new look: Typically, cancer drugs that help only a small number of patients in clinical trials are not pursued. This might change in a future world of precision medicine, where biomarkers will match specific drugs to the patients most likely to respond. Han et al. identified the mechanism of action of a cancer drug called indisulam, a sulfonamide tested previously in patients with solid tumors. Indisulam and related sulfonamides killed cells by disrupting precursor mRNA splicing. The drugs targeted a specific RNA splicing factor for degradation by “gluing” it to the CUL4-DCAF15 ubiquitin ligase. Experiments with cancer cell lines suggest that future clinical trials of these drugs should focus on leukemias and lymphomas with high DCAF15 expression levels. Science , this issue p. eaal3755
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, aryl sulphonamides degrade the essential RNA-binding protein RBM39 by engaging DCAF15, the substrate receptor of the CRL4DCAF15 E3 ubiquitin ligase13–15.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [13]
In the citing paper
“it took two decades to determine that indisulam, and the related sulfonamides e7820 and chloroquinoxaline sulfonamide (cQS), were in fact glue degraders that targeted the splicing factor RBM39 (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“indisulam facilitated an interaction between RBM39 and DcAF15, a substrate receptor component of the cRl4 DcAF15 ligase complex (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“However, sulfonamides such as indisulam and similar SPlAMs were serendipitously discovered to degrade RBM39 by stabilizing its native interaction with cRl4 DcAF15 (Han et al. 2017; uehara et al. 2017) (Figure 4A).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“The same MG mechanism has subsequently been revealed for antitumor aryl-sulfonamides, which reprograms another CRL4 substrate receptor, DCAF15, to bind and degrade certain RNA-binding proteins21–26.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [21]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · cited 1×
“8) (52) to human reference genome (hg19) along with the gene annotation data downloaded from Illumina’s iGenomes (http://support.”
MethodMass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484 · cited 2×
“As peptides eluted they were subjected to electrospray ionization and then entered into an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).”
MethodNGS QC Toolkit: A Toolkit for Quality Control of Next Generation Sequencing Data
Patel, R. K., & Jain, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030619 · Cited by 2,917
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 7×
“In many cases, ubiquitin is added to substrates by cullinRING ligases (CRLs), which are multisubunit ubiquitin ligases (23).”
BackgroundInfluentialLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688 · cited 1×
“This is the same mechanism by which the plant hormone auxin acts like “molecular glue” to enhance an interaction between the E3 ubiquitin ligase receptor TIR1 and its substrates (43).”
Background
Cited by
Items 501–600 of 786
Fantastic Molecular Glues and Where to Find them
Gillingham, D. G. (2021) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2021.439 · Cited by 6
Yang, Y. H., Li, Z., Yang, Y., Xiao, P., He, Z., Zhang, Z., Li, Y., Shi, L., Wang, X., Tao, Y., et al. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01380-3 · Cited by 6
Xun, C., Nong, Z., Hu, K., Lv, W., Zhao, J., Yin, Z., Lv, J., Jiang, F., & Gui, Q. (2025) · Organic Chemistry Frontiers · doi:10.1039/d5qo00867k · Cited by 5
Zhu, Z., Zhou, X., Xu, M., Chen, J., Robertson, K., Atassi, G., Woodcock, M. G., Mills, A., Herring, L. E., Dotti, G., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191772 · Cited by 6
Clues for glues: from serendipity to nature’s blueprints in degrader discovery
Kozicka, Z. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253058 · Cited by 6
Molecular glue degraders: Rational design, specificity engineering, and advanced delivery
Ma, L., Wang, N., Zhu, J., Wu, L., He, S., & Zhang, B. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.020 · Cited by 9
Emerging Therapies for the Myelodysplastic Syndromes
Canaani, J. (2019) · Clinical Hematology International · doi:10.2991/chi.d.191202.001 · Cited by 5
Coomar, S., Mota, P., Penson, A. V., Schwaller, J., Abdel-Wahab, O. I., & Gillingham, D. G. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0541 · Cited by 5
Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies
Boussi, L. S., Biswas, J., Abdel-Wahab, O. I., & Stein, E. M. (2024) · British Journal of Haematology · doi:10.1111/bjh.19826 · Cited by 5
The CRISP(Y) Future of Pediatric Soft Tissue Sarcomas
Pomella, S., & Rota, R. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00178 · Cited by 5
High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery
Guenette, R. G., & Potts, P. R. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.08.027 · Cited by 6
Dai, X., Cai, L., Zhang, Z., & Li, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-10860-z · Cited by 7
E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities
Basu, B., Kal, S., Karmakar, S., Basu, M., & Ghosh, M. K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122333 · Cited by 5
Hou, C., Wu, X., Shi, R., Xing, X., Tian, S., Eléouët, M. P., Qiao, C., Ma, J., & Xu, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116259 · Cited by 7
Ververs, F. A., Engelen, S. E., Nuboer, R., Vastert, S. J., van der Ent, C. K., Land, B. V., Garssen, J., Monaco, C., Boes, M. L., & Schipper, H. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-99580-7 · Cited by 5
RNA Splicing and Immune-Checkpoint Inhibition
Ding, L., & Odunsi, K. O. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2110736 · Cited by 5
Evaluation of a Pooling Chemoproteomics Strategy with an FDA-Approved Drug Library
Sun, H., Yang, K., Zhang, X., Fu, Y., Yarbro, J. M., Wu, Z., Chen, P., Chen, T., & Peng, J. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00256 · Cited by 8
Mboge, M. Y., Chen, Z., Wolff, A., Mathias, J. V., Tu, C., Brown, K. D., Bozdağ, M., Carta, F., Supuran, C. T., McKenna, R., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/345298 · Cited by 5
Discovering Nature’s super glue
Zeng, Z., & Han, T. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0586-x · Cited by 5
Self-citationShen, J., Zhou, S., & Che, X. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.03.651455 · Cited by 7
Adhikari, B., Schneider, K., Diebold, M., Sotriffer, C., & Wolf, E. (2024) · eLife · doi:10.7554/elife.98450 · Cited by 4
RBM39 Contributes to MGMT Maintenance in Response to Temozolomide-Induced DNA Damage
Khalaj, V., Adams, J. T., AghaAmiri, S., Vargas, S. H., Bateman, T. M., Ghosh, S. C., Momeny, M., & Azhdarinia, A. (2025) · Cancers · doi:10.3390/cancers17223604 · Cited by 5
Expanding the druggable proteome strategies and innovations in targeted protein degradation
Ma, K., Liu, T., Huan, W.-B., Chen, K.-Z., & Qiao, S. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102945 · Cited by 4
Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapy
Barainka, M., Zheleva, A., Pérez-Cervera, Á., Villanueva, H., Meraviglia-Crivelli, D., Moreno, B., & Pastor, F. (2026) · iScience · doi:10.1016/j.isci.2025.114597 · Cited by 4
Chang, J., Yan, S., Geng, Z., & Wang, Z. (2023) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2023.109677 · Cited by 4
Zhang, R., Zheng, Y., Xiang, F., & Zhou, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116756 · Cited by 5
Matsuhisa, K., Sato, S., & Kaneko, M. (2025) · Biomedicines · doi:10.3390/biomedicines13040854 · Cited by 6
Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 Ligases
Hussain, M. S., Babu, M. A., Afzal, M., Roopashree, R., Lal, M., Rekha, A., Oliver, B. G. G., MacLoughlin, R. J., Chakraborty, A., Dua, K., et al. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673382742250619055201 · Cited by 4
Jia, X., Zhang, J., Pan, L., He, J., Zhu, M., Zhao, L., Zhang, X., Zhao, W., Xie, D., Shen, X., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02677-5 · Cited by 5
Neddylation: from regulatory mechanisms to clinical implications in cancer
Zhang, M., Peng, Q., Feng, Y., Yang, T., Yao, W., Deng, Z., & Wang, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.11.010 · Cited by 9
Evolution and impact of molecular glue research: a bibliometric analysis from 2000 to 2023
Li, D., Cheng, J., Yuan, Z., & Deng, K. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1401257 · Cited by 5
(G)Patching up mis-splicing in cancer
Cieśla, M., & Bellodi, C. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.05.001 · Cited by 4
Liu, J., Zhang, Z., Xu, W., Jia, M., Zeng, X., Wu, C., Fu, Z., Xu, X., Ye, C., Wu, C., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015815 · Cited by 4
RBM39 shapes innate immunity by controlling the expression of key factors of the interferon response
Li, T.-F., Rothhaar, P., Lang, A., Grünvogel, O., Colasanti, O., Olivera-Ugarte, S.-M., Traut, J., Piras, A., Acosta‐Rivero, N., Magalhães, V. G., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1568056 · Cited by 6
Rees, M. G., Seashore-Ludlow, B. A., & Clemons, P. A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8891-4_14 · Cited by 4
Regulation of Stem Cells by Cullin-RING Ligase
Fu, L., Cui, C., & Zhang, L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_6 · Cited by 4
Premnath, N., & Madanat, Y. F. (2023) · Cancers · doi:10.3390/cancers15112958 · Cited by 5
Li, T., Liu, Y., Yue, S., Liao, Z., Luo, Z., Wang, M., Cao, C., Ding, Y., & Lin, Z. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01102 · Cited by 6
Yang, J., Wang, Q.-L., Feng, G., & Zeng, M. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900210 · Cited by 5
Dias, M. H., Liudkovska, V., Bleijerveld, O. B., Velds, A., Bernards, R., & Cieśla, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.12.548685 · Cited by 5
RBM39 is a potential prognostic biomarker with functional significance in hepatocellular carcinoma
Cui, F., Wang, W., Zhuang, C., He, D., & Wang, P. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2252 · Cited by 4
RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA
An, H., Xia, A., Liu, S., Luo, D., Geng, L., Li, B., Sun, B., & Xu, Z. (2025) · Cell Proliferation · doi:10.1111/cpr.70059 · Cited by 3
Molecular Glues in Immunotherapy: Fine-Tuning Immune Responses for Precision Medicine
Pandey, A., Chettupalli, A. K., Bukke, S. P. N., Yadav, S., & Anjur, D. K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115694 · Cited by 4
Yin, H., Lang, S., Lu, Y., Zhou, Z., Ren, S., Yu, X., Qiu, J., Li, Z., Wang, X., Peng, L., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09213-2 · Cited by 3
Xiong, S., Hu, L., Sun, Y.-Y., Huang, W., & Hu, X.-Y. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119025 · Cited by 5
Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer
Wagner, V., Bousset, L., Ascensão-Ferreira, M., Sun, B., Avila, J. E. B., Kaizeler, A., Martins-Silva, R., Rahbari, M., Fernández-Vaquero, M., Haston, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71564-z · Cited by 3
DCAF11-dependent molecular glue degrader activated by glutathionylation
Yoon, H., Wachter, F., Barrett, K., Jin, C., Rodríguez-Pöhnlein, A., Rutter, J. C., Lumpkin, R. J., Metivier, R. J., Donovan, K. A., Baek, K., et al. (2026) · Nature · doi:10.1038/s41586-026-10873-1 · Cited by 5
Preclinical Studies of PROTACs in Hematological Malignancies
Fuchs, O., & Bokorová, R. (2021) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x21666210308111546 · Cited by 3
Zhuang, C., Cui, F., Chen, J., He, D., Sun, T., & Wang, P. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167815 · Cited by 3
Gan, P., Zhou, X., Shah, A. M., Bezprozvannaya, S., Chen, K., Ding, Q., Li, H. Z., Xu, L., Liu, N., & Olson, E. N. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2514363122 · Cited by 3
Exon inclusion signatures enable accurate estimation of splicing factor activity
Anglada-Girotto, M., Segura-Morales, C., Moakley, D. F., Zhang, C., Miravet‐Verde, S., Califano, A., & Serrano, L. G. (2026) · Nature Communications · doi:10.1038/s41467-026-69642-3 · Cited by 4
Exome Sequencing of Drug-Resistant Clones for Target Identification
Han, T., & Nijhawan, D. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8891-4_10 · Cited by 3
Self-citationGüngör, T., Önder, F. C., Sezer, F., Özbilen, A., Taşkın, K. M., & Ay, M. (2019) · TURKISH JOURNAL OF CHEMISTRY · doi:10.3906/kim-1901-27 · Cited by 3
A Novel Prognostic Index Based on Alternative Splicing in Papillary Renal Cell Carcinoma
Wu, Z., Liu, J., Sun, R., Chen, D., Wang, K., Cao, C., & Xu, X. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2019.01333 · Cited by 3
Structural and Biophysical Principles of Degrader Ternary Complexes
Zollman, D., & Ciulli, A. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00014 · Cited by 3
Xing, N., Chen, C., Zhong, Q., Zheng, S., Wang, G., & He, L. (2020) · Molecules · doi:10.3390/molecules25225459 · Cited by 3
Tailor-made polysaccharide-based hydrogels for biomedical applications
Figueroa-Pizano, M. D., & Carvajal‐Millán, E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821344-5.00005-9 · Cited by 4
Richardson, S. S., Medhavi, F., Tanner, T., Lundy, S. R., Omosun, Y., Igietseme, J. U., Carroll, D. S., & Eko, F. O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698737 · Cited by 3
Bondeson, D. P., Smith, B. E., & Buhimschi, A. D. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_7 · Cited by 3
Promoting spliceosome assembly for therapeutic intent
Lü, B., & Abdel-Wahab, O. I. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.09.006 · Cited by 3
Targeting Cullin-RING E3 Ubiquitin Ligase 4 by Small Molecule Modulators
Wu, K., Hopkins, B. D., Sánchez, R., DeVita, R. J., & Pan, Z. (2021) · Journal of Cellular Signaling · doi:10.33696/signaling.2.051 · Cited by 7
Surgun, S., Öztaşkın, N., Çağan, A., Akıncıoğlu, A., Akıncıoğlu, H., & Göksu, S. (2024) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426507.2024.2365702 · Cited by 3
Qiao, X., Ma, D., & Zhang, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01148-0 · Cited by 3
Fabbrizi, E., Fiorentino, F., Casano, F., Mai, A., & Rotili, D. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2486146 · Cited by 4
Developmental bioengineering: recapitulating development for repair
Goldfield, E. C., & Coppens, M. (2020) · Molecular Systems Design & Engineering · doi:10.1039/d0me00062k · Cited by 3
Li, Z., He, Z., Wang, J., & Kong, G. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiac015 · Cited by 4
Targeting of Post-Transcriptional Regulation as Treatment Strategy in Acute Leukemia
Podszywalow‐Bartnicka, P., Wołczyk, M., & Piwocka, K. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94421 · Cited by 2
Overview of scaffolds processing technologies
D’Amora, U., Ronca, A., Raucci, M. G., & Ambrosio, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820508-2.00002-7 · Cited by 4
Discovery of a tau-aggregate clearing compound that covalently targets P4HB
Conway, L. P., Estrada, M. A., Li, W., Walker, S. G., Mielich‐Süss, B., Shrestha, A., Townsend, M., Korffmann, J., Potts, G. K., Lee, J. Y., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.09.006 · Cited by 2
Computational approaches enhance the design of molecular glue degraders for undruggable proteins
Deshani, S. G. M. A., Madushani, G. R. D. S., Karunaratne, V., Vinit, K., & Hao, G. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104577 · Cited by 2
Ma, Y., Poon, E., Jin, C., Costa, B. M. D., Xu, Y., Quazi, S., Zourdoumis, N., Wickremesinghe, C., Chesler, L., Keun, H. C., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116784 · Cited by 2
Liu, Y., Sun, Y., Song, T.-Y., Ni, S.-Y., Pu, Y.-S., Chang, Y. H., Zhou, W.-X., Peng, Z.-G., Liu, J., Shi, J., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3941 · Cited by 2
Okada, M., Sato, J., Funasaka, C., Yamamoto, N., Sasaki, T., Yokoyama, M., Hamada, A., Doi, T., & Mano, H. (2026) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyag031 · Cited by 2
Advantages and Challenges of G-Quadruplexes in Regulating Alternative Splicing
Huang, H., & Zhou, X. (2026) · JACS Au · doi:10.1021/jacsau.6c00168 · Cited by 2
Wang, X., Song, J., Zhao, Y., Li, W., Li, J., Xu, X., Liu, W., Tao, F., & Xu, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108239 · Cited by 3
Targeted protein degradation: bridging chemical biology and clinical translation
Zhang, Y., Fu, J.-W., Liu, Y., Wu, R. Y., Liang, Y., Zhang, W., Yuan, T., Zhu, H., He, Q.-J., & Yang, B. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01861-2 · Cited by 5
Role of post-transcriptional gene regulation in hematological malignancies
Ahmad, H. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91305-8.00007-7 · Cited by 2
Biochemical Principles of Targeted Protein Degradation
Agafonov, R. V., Deibler, R. W., Elam, W. A., Patel, J. S., & Fisher, S. L. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch10 · Cited by 2
Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo
Zhang, X., Geng, L., Yang, L. C., Wang, Y., Zou, Z., Zhang, Y., Xu, H., Lei, H., Cao, Y., Wu, Y., et al. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110837 · Cited by 2
A metabolic signalling role for arginine in liver cancer
Sokolov, D., & Sullivan, L. B. (2023) · Life Metabolism · doi:10.1093/lifemeta/load046 · Cited by 2
Frank, A. R., Vandiver, F., & McFadden, D. G. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00663 · Cited by 2
Li, A., Cui, H., & Zhao, E. (2024) · MedComm · doi:10.1002/mco2.581 · Cited by 5
Thalidomide – From a Banned Drug to Molecular Glues, PROTACs, and New Concepts in Drug Discovery
Yamamoto, J., Handa, H., & Yamaguchi, Y. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch24 · Cited by 2
Malard, F., Bouton, L., & Campagne, S. (2025) · Biomolecular NMR Assignments · doi:10.1007/s12104-025-10248-z · Cited by 2
Emerging pharmacology of targeted protein degraders
Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2
Targeted Protein Degradation: "The Gold Rush is On!"
Kotlarek, D., Pawlik, A., Sagan, M., Sowała, M., Zawiślak-Architek, A., & Walczak, M. (2020) · Technology Transfer and Entrepreneurship · doi:10.2174/2213809907666200130111436 · Cited by 2
Gołoś, A., Góra‐Tybor, J., & Robak, T. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2171860 · Cited by 2
Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A
Wu, C., Wu, C., Liu, J., Jia, M., Zeng, X., Fu, Z., He, Z., Xu, W., & Yan, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299019 · Cited by 2
ICBS 2021: Looking Toward the Next Decade of Chemical Biology
Veale, C. G. L., Talukdar, A., & Vauzeilles, B. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00209 · Cited by 2
Localized heme sensing through a ternary molecular gluePreprint
Heider, M., Hipp, C., Yang, Z., Xiao, H., Beschauner, T., Wehri, E., Walter, W., Sherriff, R., Chandrasekhar, S., Haferlach, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.07.723605 · Cited by 3
da Silva, F. C., Martinho, A. C. C., Ferreira, H. S. V., Siqueira, R. P., Arruda, V. M., Guerra, J. F. D. C., de Souza, M. L. D. R., Landin, E. S., Júnior, C. D. O. R., & Araújo, T. G. (2024) · Molecules · doi:10.3390/molecules29184471 · Cited by 1
Jean-Francois, F. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00010-3 · Cited by 1
Systematic Characterization of Splicing Dysregulation in Pan Solid Tumor Transcriptome
Sui, J., Guo, D. H., Xiao, W., Zhou, L., Huang, Y., Yu, H., Chen, J., & Liu, Z. (2024) · Advanced Science · doi:10.1002/advs.202405626 · Cited by 2
Alternative Splicing in Lung Adenocarcinoma: From Bench to Bedside
Luo, W., Xu, M., Wong, N., & Ng, C. S. H. (2025) · Cancers · doi:10.3390/cancers17081329 · Cited by 1
Drug discovery technologies–Current and future trends
Noe, M. C., Steppan, C. M., & Weston, A. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00019-4 · Cited by 1
Dai, X., Dong, B., Xu, L., & Yang, Z. (2025) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4154 · Cited by 1
Network-driven identification of indisulam neo-substrates for targeted protein degradation
Jarnuczak, A. F., Yogev, O., Andres, A., Ashenden, S. K., Cheng, Y., Pachl, F., Zhang, A., Cuomo, M. E., & Jin, M. (2025) · Molecular Omics · doi:10.1039/d5mo00053j · Cited by 2
Understanding the Role of H-Bonds in the Stability of Molecular Glue-Induced Ternary Complexes
Blanco-Gabella, P., Ivanova, V., Serrano‐Morrás, Á., Fuchs, J. E., & Juárez‐Jiménez, J. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02718 · Cited by 2
Unlocking the undruggable spliceosome: generative AI and structural dynamics in cancer therapy
Steuer, J., & Kahraman, A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1774239 · Cited by 1
Li, Y., Lu, C., Lu, J., Jiang, H., Li, D., Wang, Y., Xu, G., Wang, X., & Ma, J. (2026) · FEBS Journal · doi:10.1111/febs.70494 · Cited by 1
Metadata
- Authors
- Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Goralski, Maria
- Gaskill, Nicholas
- Nijhawan, Deepak
- ORCID
- Venue
- Science
- Published
- 2017-04-28
- Volume
- 356
- Issue
- 6336
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2596064219
- Cited by
- 762
- References
- 55
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 122 · 2023: 99 · 2022: 86 · 2021: 99 · 2020: 86 · 2019: 56 · 2018: 40 · 2017: 15
- FWCI
- 22.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Welch Foundation (I-1879)
- Damon Runyon Cancer Research Foundation (CI-68-13)
- Cancer Prevention and Research Institute of Texas (RP150596)
- Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- indisulam, sulfonamides, RBM39, DCAF15, pre-mRNA splicing, splicing inhibition, proteasomal degradation, polyubiquitination, anticancer agents, drug resistance, biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Nuclear Proteins, RNA Splicing, Sulfonamides, RNA-Binding Proteins, Mice, Knockout, Drug Resistance, Neoplasm, Amino Acid Substitution, Xenograft Model Antitumor Assays, Ubiquitin-Protein Ligase Complexes, Cell Line, Tumor, Proteasome Endopeptidase Complex, Mice, Biomarkers, Pharmacological, Ubiquitination, Molecular Targeted Therapy, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.